Healthcare Industry News: endoscope
News Release - March 19, 2009
Olympus Medical Systems in Collaboration with Medinol Ltd. Announces the Release of the X-Suit NIR(R), a Biliary Metallic Stent Featuring Exceptional Anatomic ConformabilityExpanding the Business of EndoTherapy Devices Through the Metallic Stent Market in Europe, the US and Parts of Asia
HAMBURG, Germany--(HSMN NewsFeed)--Olympus Medical Systems Corporation, in collaboration with Medinol Ltd., announces the release of the X-Suit NIR(R), a biliary metallic stent featuring exceptional anatomic conformability. This device will launch in Europe and parts of Asia on March 27, 2009 followed by the US on April 24, 2009. In Japan and other territories the product will be launched after obtaining marketing approval from the regulatory authorities. The president of Olympus Medical Systems Corporation, Haruhito Morishima, declared: “I am pleased to announce that we will soon be launching a new metallic stent which is an essential component of endoscopic treatment for biliary duct lesions. This product is the fruit of years of groundwork in collaboration with an Israeli company, Medinol. The product offers both excellent radial force and flexibility, which are crucial requirements for the stents. We can confidently recommend this high-quality stent system to our customers.”
Olympus, as a leading company of gastrointestinal endoscopes, has commercialized a variety of duodenal endoscopes and therapeutic devices for the pancreatic biliary tract to support the diagnosis and treatment of associated diseases and to meet the needs of users. Olympus will continue to enhance its range of metallic stents and expand the business by offering comprehensive value in EndoTherapy devices.
The X-Suit NIR(R) is a medical device made of a metallic mesh tube that is placed for dilating a stenosis within a vessel of the human body (i.e., blood vessel, bile duct, esophagus, trachea, and so on).
The X-Suit NIR(R) biliary metallic stent has three main features:
Unique cell geometry, called NIRflexTM Cell Design, using a shape-memory alloy
The NIRflexTM Cell Design, with alternating narrow strut rings and wide strut rings, gives the stent superior radial force and high flexibility, which are key requirements for a metallic stent. In addition, thanks to the peak-to-valley cell construction ensures the stent surface remains smooth and point-free even when bent at a sharp angle, while the closed cell construction ensures that the struts are fully apposed to the bile duct wall.
Moreover, there is virtually no foreshortening after the stent is released from the delivery catheter, and the stent can be placed precisely at the target position.
Superior radial support and high flexibility
The wide strut rings provide outstanding radial support, and the narrow strut rings function to release the force applied cross-sectionally in the longitudinal axis direction, giving the stent excellent flexibility. This enables the stent to fit any bile duct, even if highly curved, without buckling, and reduces the risk of restenosis.
Outstanding insertion and stable deployment performance of stent delivery catheter
The delivery catheter with its optimal tapering shape and hardness of the distal tip facilitates insertion into the papilla and passage through a stenosis in a bile duct. Also, the intermediate tube minimizes variations of the inner diameter even when the catheter is bent, allowing excellent deployment at a constant force from start to finish.
Corporate data of Medinol Ltd.
Name: Medinol Ltd. (www.medinol.com)
CEO: Dr. Judith Richter
Address: Bldg. 7, Entrance A, 5th floor Kiryat Atidim, PO Box 58165, Tel Aviv, 61581, Israel
Number of employees: Approximately 200
Activities: Development and manufacturing of metallic stent and stentingsystems for all medical applications.
Note: The company names and product names specified in this release are the trademarks or registered trademarks of each company.
Source: Olympus Medical Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.